We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Based on Genetic Biomarkers Detects Atrial Fibrillation

By LabMedica International staff writers
Posted on 15 Oct 2014
Heart disease researchers have developed a DNA-based blood test that identifies individuals with atrial fibrillation and predicts likelihood of suffering ischemic stroke.

Atrial fibrillation (AF) is the most common abnormal heart rhythm. More...
It may cause no symptoms, but is often associated with palpitations, fainting, chest pain, or congestive heart failure. The cause of an individual's AF may not be identified. The risk of stroke is increased five-fold in individuals with AF. AF may be identified clinically when taking the pulse and its presence can be confirmed with an electrocardiogram (ECG) that demonstrates the absence of P waves and an irregular ventricular rate. AF may occur in episodes lasting from minutes to days or may be permanent in nature. Many medical conditions increase the risk of AF, in particular mitral stenosis (narrowing of the mitral valve of the heart).

Investigators at Lund University (Sweden) examined the possibility that genetic biomarkers could be used to detect AF. To this end they created an AF genetic risk score (AF-GRS) based on twelve genetic variants (single nucleotide polymorphisms or SNPs) in the human genome that were linked to increased risk of atrial fibrillation.

The investigators evaluated samples from In 27,471 participants of the Malmö Diet and Cancer Study, a prospective, community-based cohort, to assess the association of AF-GRS with incident AF and ischemic stroke. Median follow-up was 14.4 years for incident AF and 14.5 years for ischemic stroke.

During the follow-up period, 2160 participants experienced a first AF event and 1495 had a first ischemic stroke event. Participants in the top 20% of AF-GRS were at increased risk for incident AF and ischemic stroke when compared with the bottom 20%. Patients who had already been diagnosed with atrial fibrillation and carried the panel of 12 SNPs had their risk of stroke increased by a further 70%–80%.

"One in five people have a genetic weakness that means they have twice as high a risk of developing atrial fibrillation as those with a low genetic risk. This genetic risk is therefore one of the strongest risk factors for atrial fibrillation that we know of in people without overt cardiac disease. It increases the risk as much as high blood pressure, for example", said senior author Dr. Olle Melander, professor of internal medicine at Lund University. "In patients who are suspected of having temporary but recurrent episodes of atrial fibrillation, or in people with high blood pressure, it can be important for doctors to look at their genetic predisposition using a blood test. The test can give guidance as to how often and how intensively doctors need to screen for presence of atrial fibrillation in these individuals. We also consider that more widespread treatment of high blood pressure may be justified in those with a high genetic risk of atrial fibrillation."

The study was published in the October 2014 issue of the journal Stroke.

Related Links:

Lund University



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.